BTdCPU

Item no.	DCC-DC32550-250mg
Manufacturer	DCChemicals
CASRN	1257423-87-2
Amount	250 mg
Quantity options	100 mg 1 g 250 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	>98%
Smiles	O=C(NC1=CC=C(Cl)C(Cl)=C1)NC2=CC=C3N=NSC3=C2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Available
Manufacturer - Applications	BTdCPU is an activator of HRI. The eIF2-alpha kinase HRI is a novel therapeutic target in multiple myeloma. Combination therapy with rapamycin, an mTOR inhibitor, and BTdCPU, an activator of HRI, demonstrated additive effects on apoptosis in dex-resistant cells. Thus, specific activation of the eIF2α kinase HRI is a novel therapeutic target in MM that can augment current treatment strategies.
Molecular Weight	339, 194

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 250 mg

available

Delivery expected until 2/26/2026

Compare

Add to wishlist

Get an offer

Request delivery time